DIAMEDICA THERAPEUTICS INC

Company Overview

DiaMedica Therapeutics (DMAC) is a clinical-stage biopharmaceutical company developing DM199 (rinvecalinase alfa), a recombinant form of human tissue kallikrein‑1, as a potential therapy for acute ischemic stroke (AIS) and preeclampsia (PE), with a longer‑term program for severe acute pancreatitis. The company is R&D‑centric (28 employees at year‑end 2024) and outsources biologics manufacturing to Catalent under license and milestone/royalty arrangements. DiaMedica has no product revenues, is advancing an adaptive Phase 2/3 ReMEDy2 AIS trial and investigator‑sponsored PE studies, and is dependent on trial enrollment, regulatory milestones (FDA Fast Track for AIS), CDMO performance, and capital markets to reach commercialization.

Executive Compensation Practices

With no product revenue and rising R&D spend, DiaMedica’s compensation mix is likely weighted toward equity and performance‑linked awards to conserve cash; filing disclosures already show non‑cash share‑based compensation is a material component of G&A. Key pay drivers for executives will be clinical milestones (e.g., ReMEDy2 enrollment/ interim analyses, IND filings and Part 1a/1b PE results), regulatory progress toward a BLA pathway, and successful partnering or financings that extend runway. Given tight cash runway dynamics and the small headcount, retention and hiring of experienced clinical and regulatory staff likely use equity‑based incentives plus smaller cash bonuses tied to program advancement; valuation of awards will reflect high implied volatility typical of biotech (company uses Black‑Scholes inputs). License and CDMO milestones (Catalent exclusivity, approval milestone at first regulatory approval, low single‑digit royalties) also create discrete event pay triggers for long‑term incentive design.

Insider Trading Considerations

As a small, clinical‑stage biotech in the Healthcare/Biotechnology sector, DMAC’s equity is likely to be highly volatile around trial enrollment updates, interim safety/efficacy readouts (e.g., PE Part 1a), IND/approval news, and financing announcements — all events that can materially affect insider trading behavior. Insiders will be subject to Section 16 reporting and typical blackout windows around material nonpublic information (site activations, interim results, IND filings, financings) and may use Rule 10b5‑1 plans or pre‑planned sales to manage tax obligations from option exercises and limit appearance of opportunistic sales; observers should watch for open‑market purchases as a higher‑conviction signal given limited insider cash exposure. Elevated share‑based compensation and frequent financings increase the likelihood of insider sales to cover tax liabilities or option exercises, so clusters of sales ahead of dilutive financings or immediately after funding closes warrant scrutiny. Regulatory and clinical holds or safety signals (historically a transient hypotension hold) amplify both trading sensitivity and stricter internal compliance controls.